DOCSLIB.ORG

Aurothioglucose/Benzydamine Hydrochloride 27 2

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Aurothioglucose/Benzydamine Hydrochloride 27 2 Aurothioglucose/Benzydamine Hydrochloride 27 2. Albazzaz MK, et al. Alveolitis and haemolytic anaemia induced Profile that have occurred with benoxaprofen include skin disorders, by azapropazone. BMJ 1986; 293: 1537–8. Bendazac is an NSAID (p.96) structurally related to indometacin notably photosensitivity reactions but also erythema multiforme 3. Montgomery RD, Babb RG. Alveolitis and haemolytic anaemia (p.66). It has been used topically in preparations containing 1 or and the Stevens-Johnson syndrome, onycholysis and other nail induced by azapropazone. BMJ 1987; 294: 375. 3% for the treatment of various inflammatory skin disorders. disorders, gastrointestinal disturbances including peptic ulcera- Effects on the gastrointestinal tract. In a review1 of the rel- Bendazac lysine has been used in the management of cataract, tion and bleeding, blood disorders such as thrombocytopenia, ative safety of 7 oral NSAIDs, the UK CSM commented that eye drops containing 0.5% being instilled three times daily. cholestatic jaundice and other liver or biliary disorders, and renal azapropazone was associated with the highest risk of gastrointes- Hepatotoxicity has been reported. failure. tinal reactions in both epidemiological studies and an analysis of spontaneous reporting of adverse reactions. Although it appeared ◊ References. that some patients over 60 years of age had received doses ex- 1. Balfour JA, Clissold SP. Bendazac lysine: a review of its phar- ceeding those recommended for this age group, it was considered macological properties and therapeutic potential in the manage- Benzydamine Hydrochloride (BANM, USAN, rINNM) that even when this was taken into account a marked difference ment of cataracts. Drugs 1990; 39: 575–96. 2. Prieto de Paula JM, et al. Hepatotoxicidad por bendazaco: análi- AF-864; Benzidamin Hidroklorür; Benzindamine Hydrochloride; remained between gastrointestinal reactions for azapropazone sis de 16 casos. Rev Clin Esp 1995; 195: 387–9. Benzydamine, Chlorhydrate de; Benzydamini Hydrochloridum; compared with other NSAIDs. Preparations Benzydaminy chlorowodorek; Hidrocloruro de bencidamina. 3- The CSM recommended that azapropazone should be restricted (1-Benzyl-1H-indazol-3-yloxy)-NN-dimethylpropylamine hydro- to use in rheumatoid arthritis, ankylosing spondylitis, and acute Proprietary Preparations (details are given in Part 3) Austria: Versus; Gr.: Versalba; Ital.: Bendalina; Versus; Philipp.: Bendalina; chloride. gout and only when other NSAIDs have been ineffective. Its use Port.: Bendalina; Venez.: Bendalina. in patients with a history of peptic ulceration was contra-indicat- Бензидамина Гидрохлорид ed. It was also recommended that when used in patients over 60 C19H23N3O,HCl = 345.9. years of age for rheumatoid arthritis or ankylosing spondylitis CAS — 642-72-8 (benzydamine); 132-69-4 (benzydam- the dose should be restricted to a maximum of 600 mg daily. Benorilate (BAN, rINN) ine hydrochloride). Azapropazone has been withdrawn in many countries including Benorilaatti; Benorilat; Bénorilate; Benorilato; Benorilatum; ATC — A01AD02; G02CC03; M01AX07; M02AA05. the UK. Benorylate; FAW-76; Fenasprate; Win-11450. 4-Acetamidophe- ATC Vet — QA01AD02; QG02CC03; QM01AX07; QM02AA05. 1. CSM/MCA. Relative safety of oral non-aspirin NSAIDs. Cur- nyl O-acetylsalicylate. rent Problems 1994; 20: 9–11. Also available at: http:// www.mhra.gov.uk/home/idcplg?IdcService=GET_ Бенорилат FILE&dDocName=CON2015615&RevisionSelectionMethod= C17H15NO5 = 313.3. LatestReleased (accessed 01/11/07) CAS — 5003-48-5. ATC — N02BA10. Effects on the skin. Of 917 reports of adverse reactions asso- N ciated with azapropazone forwarded to the WHO Collaborating ATC Vet — QN02BA10. Centre for International Drug Monitoring1 before September N 1984, 190 (21%) were of photosensitivity. Of 154 reports of pho- CH O 3 tosensitivity evaluated a causal relationship to use of azapropa- H O N zone was considered certain in 6, probable in 138, and possible N CH3 in 10. In May 1994 the UK CSM stated2 that since 1976 they had 3C OH O CH3 received 464 reports of photosensitivity reactions associated with azapropazone and commented that, when corrected for pre- O (benzydamine) scription volume, reporting of this reaction was 50 times greater O than with other commonly prescribed NSAIDs. They recom- Pharmacopoeias. In Br. and Pol. mended that patients should be advised to avoid direct exposure BP 2008 (Benzydamine Hydrochloride). A white crystalline to sunlight or to use sunblock preparations. powder. Very soluble in water; freely soluble in alcohol and in 1. Olsson S, et al. Photosensitivity during treatment with azapropa- Pharmacopoeias. In Br. and Chin. BP 2008 (Benorilate). A white or almost white, odourless or al- chloroform; practically insoluble in ether. A 10% solution in wa- zone. BMJ 1985; 291: 939. ter has a pH of 4.0 to 5.5. 2. CSM/MCA. Photosensitivity associated with azapropazone most odourless, crystalline powder. Practically insoluble in wa- (Rheumox). Current Problems 1994; 20: 6. Also available at: ter; sparingly soluble in alcohol and in methyl alcohol; soluble in Adverse Effects http://www.mhra.gov.uk/home/idcplg?IdcService=GET_ acetone and in chloroform. After topical application to the skin local reactions such as ery- FILE&dDocName=CON2015616&RevisionSelectionMethod= LatestReleased (accessed 01/11/07) Profile thema or rash may occur and photosensitivity has been reported. After use as mouth and throat preparations, numbness or stinging Porphyria. Azapropazone is considered to be unsafe in patients Benorilate is an aspirin-paracetamol ester with analgesic, anti- inflammatory, and antipyretic properties. After absorption, it is sensations of the oral mucosa have been reported; hypersensitiv- with porphyria because it has been shown to be porphyrinogenic ity reactions including urticaria, photosensitivity, and bronchos- in animals. rapidly metabolised to salicylate and paracetamol. It has been used orally in the treatment of mild to moderate pain (see Choice pasm may also occur rarely. Preparations of Analgesic, p.2) and fever (p.10). It has also been used in oste- Effects on the kidneys. A 57-year-old woman who had used BP 2008: Azapropazone Capsules; Azapropazone Tablets. oarthritis, rheumatoid arthritis, and soft-tissue rheumatism. 400 g of a topical cream containing benzydamine hydrochloride Proprietary Preparations (details are given in Part 3) When an overdose of benorilate is suspected, it has been suggest- 3% over a period of 4 months was found to have raised plasma Arg.: Debelex†; Austria: Prolixan†; Gr.: Prolixan†; Hung.: Prolixan†; Irl.: ed that plasma concentrations of both salicylate and paracetamol concentrations of creatinine and urea consistent with a substan- Rheumox†; Port.: Prolixan†; S.Afr.: Rheumox; Turk.: Prodisan; UK: Rheu- should be measured since a normal plasma-paracetamol concen- tial reduction in glomerular filtration rate.1 mox†. tration cannot necessarily be assumed from a normal plasma-sal- 1. O’Callaghan CA, et al. Renal disease and use of topical non- icylate measurement. steroidal anti-inflammatory drugs. BMJ 1994; 308: 110–11. ◊ References. Effects on the skin. Photoallergic contact dermatitis devel- Bendazac (BAN, USAN, rINN) 1. Aylward M. Toxicity of benorylate. BMJ 1973; 2: 118. oped on the hands of a 65-year-old woman after the use of a gen- 1 AF-983; Bendazaco; Bendazacum; Bindazac. (1-Benzyl-1H-inda- 2. Symon DNK, et al. Fatal paracetamol poisoning from benorylate ital wash containing benzydamine 0.1% for several years. The zol-3-yloxy)acetic acid. therapy in child with cystic fibrosis. Lancet 1982; ii: 1153–4. lesions disappeared once the patient stopped using the solution. Preparations 1. Lasa Elgezua O, et al. Photoallergic hand eczema due to benzy- Бендазак damine. Eur J Dermatol 2004; 14: 69–70. BP 2008: Benorilate Oral Suspension; Benorilate Tablets. C16H14N2O3 = 282.3. 1 CAS — 20187-55-7. Proprietary Preparations (details are given in Part 3) Overdose. A 6-year old girl had hallucinations after receiving 500 mg of benzydamine orally; it had been intended as a vaginal ATC — M02AA11; S01BC07. Belg.: Duvium†; Fr.: Salipran†; Irl.: Benoral†; Switz.: Duvium†; UK: Beno- ral†. douche for pruritus vulvae; recovery was spontaneous. ATC Vet — QM02AA11; QS01BC07. 1. Gómez-López L, et al. Acute overdose due to benzydamine. Hum Exp Toxicol 1999; 18: 471–3. OH Benoxaprofen (BAN, USAN, rINN) Uses and Administration O Benoksaprofeeni; Bénoxaprofène; Benoxaprofeno; Benoxapro- Benzydamine hydrochloride is an NSAID (p.99). It is used topi- fenum; Compound 90459; LRCL-3794. 2-[2-(4-Chlorophe- cally on the skin in concentrations of 3 to 5% in painful muscu- loskeletal and soft-tissue disorders. Benzydamine hydrochloride O nyl)benzoxazol-5-yl]propionic acid. is also used as a mouthwash or spray in concentrations of 0.15% Беноксапрофен for the relief of inflammatory conditions of the mouth and throat. C H ClNO = 301.7. N 16 12 3 It has been given orally or rectally for the relief of painful and CAS — 51234-28-7. inflammatory conditions, and as a topical solution for vaginal ir- N ATC — M01AE06. rigation. ATC Vet — QM01AE06. Benzydamine salicylate (benzasal) has been used topically on the skin as a 6% cream or spray. O Mouth disorders. Results of a randomised placebo-controlled study in patients undergoing radiotherapy for oropharyngeal can- Cl COOH cer indicated that benzydamine as an oral rinse was effective in Bendazac Lysine (BANM, rINNM) N reducing the area and severity of mucositis.1 Benzydamine is AF-1934; Bendazac
Load more

Recommended publications
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • FORMULATION and EVALUATION of COLON TARGETED PELLETS of BUMADIZONE CALCIUM” Mr
    THESIS ISSN: 2349-2678 Contents lists available at www.ijpba.in International Journal of Pharmaceutical and Biological Science Archive PubMed (National Library of Medicine ID: 101738825) Index Copernicus Value 2017: 71.80 Volume 7 Issue 3; May-June; 2019; Page No. 01-69 “FORMULATION AND EVALUATION OF COLON TARGETED PELLETS OF BUMADIZONE CALCIUM” Mr. Shah Akashkumar Nareshkumar1, Mr. Anil G. Raval2 1PG Research Scholar, Department of Pharmaceutics, Sharda School of Pharmacy, Pethapur, Gandhinagar, Gujarat 2Assistant Professor, Department of Pharmaceutics, Sharda School of Pharmacy, Pethapur, Gandhinagar, Gujarat ABSTRACT Aim: The aim of this study was to Formulation and Evaluation of colon targeted pellets of Bumadizone Calcium Objective: Bumadizone Calcium is an acetic acid derivative, having irritation in stomach. Bumadizone Calcium has short half-life (4hrs) and undergoes first pass metabolism. It is pH-dependent. This research work was carried out to improve the bioavailability, patient compliance on oral colon targeted drug delivery. Bumadizone Calcium sustained release enteric coated pellets were prepared, which minimize the release of drug in stomach for treatment of IBD formulated by Extrusion Spheronization process. Experimental work done: Enteric coated pellets prepared by Extrusion Spheronization technique. Eudragit S100, HPMC, PVP K30, and Ethyl Cellulose were used as rate controlling polymers. In this study, a pH dependent colon targeted enteric coated pellets was established using 32 full factorial design by giving enteric coating with Eudragit S100. Different Concentration of Eudragit S100 as an enteric coating material (4%, 5%, & %6) and PVP K30 as a Binder (0.5%, 1% & 1.5%) are taken for the measurements of % Drug Release that are performed by using USP dissolution 1 (Basket type) at 50 rpm.
    [Show full text]
  • Søgeprotokol for Nationale Kliniske Retningslinjer
    Søgeprotokol for nationale kliniske retningslinjer Projekttitel/aspekt NKR behandling af patienter med lumbal spinalstenose – Søgning efter primærlitteratur Fagkonsulent /projektleder Rikke Rousing / Maria Herlev Ahrenfeldt Søgespecialist Kirsten Birkefoss Senest opdateret 23.12.2016 Fokuserede spørgsmål Bør patienter med lumbal spinalstenose have tilbudt aktiv PICO 1: behandling i form af superviseret træning fremfor vanlig behandling? PICO 2: Bør patienter med lumbal spinalstenose have tilbudt ledmobiliserende behandling frem for vanlig behandling? PICO 3: Bør patienter med lumbal spinalstenose have tilbudt paracetamol frem for ingen smertestillende behandling? PICO 4: Bør patienter med lumbal spinalstenose have tilbudt non steroid antiinflammatorisk medicin (NSAID) frem for ingen smertestillende behandling? PICO 5: Bør patienter med lumbal spinalstenose have tilbudt smertestillende medicin i form af opioider i tillæg til eventuel behandling med svage smertestillende? PICO 6: Bør patienter med lumbal spinalstenose have tilbudt muskelrelaxantia i tillæg til eventuel behandling med svage smertestillende? PICO 7: Bør patienter med lumbaspinalstenose have tilbudt medicin for neuropatiske smerter? PICO 8: Bør patienter med lumbal spinalstenose have tilbudt kirurgisk dekompression i tilfælde af manglende effekt af ikke kirurgisk behandling? PICO 9: Bør patienter med lumbal spinalstenose have tilbudt stivgørende operation med eller uden instrumentering i tillæg til dekompression? PICO 10: Bør patienter opereret for lumbal spinalstenose tilbydes
    [Show full text]
  • Bumadizone Calcium Dihydrate Microspheres Compressed Tablets for Colon Targeting: Formulation, Optimization and in Vivo Evaluation in Rabbits
    http://informahealthcare.com/drd ISSN: 1071-7544 (print), 1521-0464 (electronic) Drug Delivery, Early Online: 1–12 ! 2014 Informa Healthcare USA, Inc. DOI: 10.3109/10717544.2014.889779 RESEARCH ARTICLE Bumadizone calcium dihydrate microspheres compressed tablets for colon targeting: formulation, optimization and in vivo evaluation in rabbits Samia A. Nour, Nevine Shawky Abdelmalak, and Marianne J. Naguib Faculty of Pharmacy, Department of Pharmaceutics, Cairo University, Cairo, Egypt Abstract Keywords The objective of this study was the development of a colon-targeted microspheres which were Bumadizone calcium, colon targeting, compressed into tablets containing the non-steroidal anti-inflammatory bumadizone calcium histopathology, microspheres compressed 2 dihydrate. A 3 full factorial design was adopted for the evaluation of the prepared into tablets, myeloperoxidase activity, microspheres. The effect of two independent variables namely polymer type (Eudragit RS100, pharmacokinetic parameters ethyl cellulose and cellulose acetate butyrate), and drug: polymer ratio (1:1, 9:1 and 18:1) was studied on the entrapment efficiency and in vitro drug release for 12 h. Colon targeting aims History to minimize the release of the drug off target area (pH 1.2 and 6.8) and to maximize the release of the drug in target area (pH 7.4). Candidate formulae were compressed into core tablets Received 12 January 2014 and colon targeting was achieved using the enzyme-dependent polymer (pectin) as coat in Revised 26 January 2014 three different concentrations 50, 75 and 90%. Candidate formula F15 (microspheres prepared Accepted 28 January 2014 using BDZ:CAB in a ratio of 18:1 and compressed into tablets using 50% pectin and 50% Avicel in the coat) was able to adequately modulate drug release avoiding drug release in the gastric ambient, and reaching the colonic targeting where 99.7% release was achieved within 12 h following zero-order model.
    [Show full text]
  • 2 12/ 35 74Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 22 March 2012 (22.03.2012) 2 12/ 35 74 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 9/16 (2006.01) A61K 9/51 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 9/14 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/EP201 1/065959 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 14 September 201 1 (14.09.201 1) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, (25) Filing Language: English RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, (26) Publication Language: English TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 61/382,653 14 September 2010 (14.09.2010) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant (for all designated States except US): GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, NANOLOGICA AB [SE/SE]; P.O Box 8182, S-104 20 ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, Stockholm (SE).
    [Show full text]
  • WO 2013/020527 Al 14 February 2013 (14.02.2013) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2013/020527 Al 14 February 2013 (14.02.2013) P O P C T (51) International Patent Classification: (74) Common Representative: UNIVERSITY OF VETER¬ A61K 9/06 (2006.01) A61K 47/32 (2006.01) INARY AND PHARMACEUTICAL SCIENCES A61K 9/14 (2006.01) A61K 47/38 (2006.01) BRNO FACULTY OF PHARMACY; University of A61K 47/10 (2006.01) A61K 9/00 (2006.01) Veterinary and Pharmaceutical Sciences Brno Faculty Of A61K 47/18 (2006.01) Pharmacy, Palackeho 1/3, CZ-61242 Brno (CZ). (21) International Application Number: (81) Designated States (unless otherwise indicated, for every PCT/CZ20 12/000073 kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (22) Date: International Filing BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, 2 August 2012 (02.08.2012) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (25) Filing Language: English HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (26) Publication Language: English ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (30) Priority Data: NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, 201 1-495 11 August 201 1 ( 11.08.201 1) SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, 2012- 72 1 February 2012 (01.02.2012) TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, 2012-5 11 26 July 2012 (26.07.2012) ZW.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of - Medicines belonging to the ATC group M01 (Antiinflammatory and antirheumatic products) Table of Contents Page INTRODUCTION 6 DISCLAIMER 8 GLOSSARY OF TERMS USED IN THIS DOCUMENT 9 ACTIVE SUBSTANCES Phenylbutazone (ATC: M01AA01) 11 Mofebutazone (ATC: M01AA02) 17 Oxyphenbutazone (ATC: M01AA03) 18 Clofezone (ATC: M01AA05) 19 Kebuzone (ATC: M01AA06) 20 Indometacin (ATC: M01AB01) 21 Sulindac (ATC: M01AB02) 25 Tolmetin (ATC: M01AB03) 30 Zomepirac (ATC: M01AB04) 33 Diclofenac (ATC: M01AB05) 34 Alclofenac (ATC: M01AB06) 39 Bumadizone (ATC: M01AB07) 40 Etodolac (ATC: M01AB08) 41 Lonazolac (ATC: M01AB09) 45 Fentiazac (ATC: M01AB10) 46 Acemetacin (ATC: M01AB11) 48 Difenpiramide (ATC: M01AB12) 53 Oxametacin (ATC: M01AB13) 54 Proglumetacin (ATC: M01AB14) 55 Ketorolac (ATC: M01AB15) 57 Aceclofenac (ATC: M01AB16) 63 Bufexamac (ATC: M01AB17) 67 2 Indometacin, Combinations (ATC: M01AB51) 68 Diclofenac, Combinations (ATC: M01AB55) 69 Piroxicam (ATC: M01AC01) 73 Tenoxicam (ATC: M01AC02) 77 Droxicam (ATC: M01AC04) 82 Lornoxicam (ATC: M01AC05) 83 Meloxicam (ATC: M01AC06) 87 Meloxicam, Combinations (ATC: M01AC56) 91 Ibuprofen (ATC: M01AE01) 92 Naproxen (ATC: M01AE02) 98 Ketoprofen (ATC: M01AE03) 104 Fenoprofen (ATC: M01AE04) 109 Fenbufen (ATC: M01AE05) 112 Benoxaprofen (ATC: M01AE06) 113 Suprofen (ATC: M01AE07) 114 Pirprofen (ATC: M01AE08) 115 Flurbiprofen (ATC: M01AE09) 116 Indoprofen (ATC: M01AE10) 120 Tiaprofenic Acid (ATC:
    [Show full text]
  • Method and Use for Increasing Efficacy of Anti-Adhesive Compositions in Controlling Inflammation and Pain
    (19) & (11) EP 2 465 513 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 20.06.2012 Bulletin 2012/25 A61K 31/77 (2006.01) A61K 33/06 (2006.01) A61K 45/06 (2006.01) A61P 29/00 (2006.01) (21) Application number: 11195175.2 (22) Date of filing: 12.11.2007 (84) Designated Contracting States: (72) Inventor: Chamness, Kathy L. AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Memphis, TN 38104-5305 (US) HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR (74) Representative: O’Connell, Maura et al FRKelly (30) Priority: 13.11.2006 US 598397 27 Clyde Road Ballsbridge (62) Document number(s) of the earlier application(s) in Dublin 4 (IE) accordance with Art. 76 EPC: 07864257.6 / 2 104 505 Remarks: •This application was filed on 22-12-2011 as a (71) Applicant: Warsaw Orthopedic, Inc. divisional application to the application mentioned Warsaw, IN 46581 (US) under INID code 62. •Claims filed after the date of filing of the application (Rule 68(4) EPC). (54) Method and use for increasing efficacy of anti-adhesive compositions in controlling inflammation and pain (57) The invention discloses a method and kit thereof prising an effective amount of at least one pharmaceuti- for increasing the efficiency of anti-adhesive composi- cally-acceptable anti-adhesive non-ionic polymer to a tions by parenterally administering a composition com- site of injury, controlling inflammation at the site of injury, and reducing pain. EP 2 465 513 A2 Printed by Jouve, 75001 PARIS (FR) EP 2 465 513 A2 Description FIELD OF THE INVENTION 5 [0001] The present invention relates to methods of increasing efficacy of anti-adhesive compositions by parental administration of compositions containing anti-adhesive polymers and magnesium salts.
    [Show full text]
  • WHO-EMP-RHT-TSN-2018.1-Eng.Pdf
    WHO/EMP/RHT/TSN/2018.1 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization [2018] Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO.
    [Show full text]
  • Pharmaceuticals (Monocomponent Products) ………………………..………… 31 Pharmaceuticals (Combination and Group Products) ………………….……
    DESA The Department of Economic and Social Affairs of the United Nations Secretariat is a vital interface between global and policies in the economic, social and environmental spheres and national action. The Department works in three main interlinked areas: (i) it compiles, generates and analyses a wide range of economic, social and environmental data and information on which States Members of the United Nations draw to review common problems and to take stock of policy options; (ii) it facilitates the negotiations of Member States in many intergovernmental bodies on joint courses of action to address ongoing or emerging global challenges; and (iii) it advises interested Governments on the ways and means of translating policy frameworks developed in United Nations conferences and summits into programmes at the country level and, through technical assistance, helps build national capacities. Note Symbols of United Nations documents are composed of the capital letters combined with figures. Mention of such a symbol indicates a reference to a United Nations document. Applications for the right to reproduce this work or parts thereof are welcomed and should be sent to the Secretary, United Nations Publications Board, United Nations Headquarters, New York, NY 10017, United States of America. Governments and governmental institutions may reproduce this work or parts thereof without permission, but are requested to inform the United Nations of such reproduction. UNITED NATIONS PUBLICATION Copyright @ United Nations, 2005 All rights reserved TABLE OF CONTENTS Introduction …………………………………………………………..……..……..….. 4 Alphabetical Listing of products ……..………………………………..….….…..….... 8 Classified Listing of products ………………………………………………………… 20 List of codes for countries, territories and areas ………………………...…….……… 30 PART I. REGULATORY INFORMATION Pharmaceuticals (monocomponent products) ………………………..………… 31 Pharmaceuticals (combination and group products) ………………….……........
    [Show full text]
  • Analytical Study of Selected Anti-Inflammatory Drugs
    Analytical Study of Selected Anti-Inflammatory Drugs Thesis Presented by Enas Taha Abdelhamed M.Sc. in Pharmaceutical Sciences Pharmaceutical Chemistry Faculty of Pharmacy - Cairo University 2012 Submitted for The Degree of Doctor of Philosophy In Pharmaceutical Sciences (Pharmaceutical Chemistry) Under the supervision of Prof. Dr. Sonia Talat Hassib Professor of Pharmaceutical Chemistry Faculty of Pharmacy - Cairo University Prof. Dr. Ghaneya Sayed Hassan Professor of Pharmaceutical Chemistry Faculty of Pharmacy - Cairo University Prof. Dr. Asmaa Ahmed El-Zaher Professor of Pharmaceutical Chemistry Faculty of Pharmacy - Cairo University Dr. Marwa Ahmed Fouad Associate Professor of Pharmaceutical Chemistry Faculty of Pharmacy - Cairo University Faculty of Pharmacy Cairo University 2018 Abstract Four simple, accurate, sensitive and economic Attenuated Total Reflectance-Fourier Transform Infrared Spectroscopic (ATR-FTIR) methods have been developed for the quantitative estimation of some non-steroidal anti- inflammatory drugs alone or in presence of related substances. The first method involves the determination of etodolac by direct measurement of the absorbance at 1716 cm-1. In the second method, the second derivative of the IR spectra of tolfenamic acid and its imperity (2-chlorobenzoic acid) was used and the amplitudes were measured at 1084.27 cm-1 and 1058.02 cm-1 for tolfenamic acid and 2-chlorobenzoic acid, respectively. The third method used the first derivative of the IR spectra of bumadizone and its reported degradation product, N,N-diphenylhydrazine and the amplitudes were measured at 2874.98 cm-1 and 2160.32 cm-1 for bumadizone and N,N-diphenylhydrazine, respectively. The fourth method depends on measuring the amplitude of diacerein at 1059.18 cm-1 and of rhein, its reported degradation product, at 1079.32 cm-1 in their first derivative spectra.
    [Show full text]